RTRX stock forecast
Our latest prediction for Retrophin, Inc.'s stock price was made on the Jan. 8, 2020 when the stock price was at 15.18$.
In the short term (2weeks), RTRX's stock price should underperform the market by -5.30%. During that period the price should oscillate between -8.76% and +7.36%.
In the medium term (3months), RTRX's stock price should underperform the market by -8.53%. During that period the price should oscillate between -29.78% and +17.15%.Get email alerts
About Retrophin, Inc.
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
At the moment the company generates 172M USD in revenues.
On its last earning announcement, the company reported a loss of -2.93$ per share.
The book value per share is 7.05$
Three months stock forecastJan. 8, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|